Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial
about
Antiviral drugs for viruses other than human immunodeficiency virusThe importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysisDirect acting antivirals for the treatment of chronic viral hepatitisNucleoside/nucleotide analogues in the treatment of chronic hepatitis BSafety and efficacy of telbivudine for the treatment of chronic hepatitis BAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease.Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis BA Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Antiviral treatment of chronic hepatitis B virus (HBV) infectionsA low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B.52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis BSystematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.Telbivudine in the treatment of chronic hepatitis B.Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.Safety and efficacy of entecavir for the treatment of chronic hepatitis B.Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysisPretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B.Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study.Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.Evaluation and treatment of the patient coinfected with hepatitis B and HIV.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.Hepatitis B and liver transplantation: 2008 update.Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis.Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovirOn-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48.A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.Treatment of chronic hepatitis B: focus on telbivudine.Chronic hepatitis B: who to treat and which choice of treatment?Benefits and risks of combination therapy for hepatitis B.Then and now: the progress in hepatitis B treatment over the past 20 years.Predictors of treatment response in chronic hepatitis B.Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational StudyHepatitis B therapies and antiviral resistance detection and management.On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.
P2860
Q24635330-16047F79-3941-476F-BB67-DF0083284F73Q27016075-ED94C0BC-C1E7-4CA1-AB77-5556F2641D1EQ27022216-F3B2695A-B79C-42F3-A891-4358F7DB4E63Q27030828-5A3B1553-EF97-416C-A5B2-7ACDC7BEF1E7Q28972486-109AA78E-7321-4658-93CA-028F95F9DE33Q30391932-EAEF83C2-9B89-41AA-8457-C61774D1E603Q30829485-8DC3B847-9745-4215-B571-3A2E1BECEE3CQ33385813-D2ECAE1A-2FF2-4DDE-8233-D7C541AF212DQ33676349-FEBC3F5B-9F55-44E1-B176-7507AA3A052CQ33819098-98DAFB52-203A-493F-8564-59E77513D594Q34223779-549F10ED-322C-435A-AFD2-46CFA660E1B0Q34494102-56EC5697-770D-4D1D-8CF8-031375863B31Q34579911-CD38767E-EEB9-4EB7-9E2D-05595BBE8030Q34594403-5FA783FD-5F0B-4050-996B-3FB13C02AAD9Q34601513-66720B99-C892-4A03-ABF0-54E9D0D12C01Q34604670-5A814B32-B095-46E8-83DF-E7DFDD46FE59Q34999403-6520BA95-B400-4672-A7DE-88C7D35DE7FBQ35026611-BEC31A64-7D45-48EB-AFAC-D71958AB1E44Q35132805-B6DBC483-D786-40D0-9E93-546B23B9D37DQ35833216-E5519574-DBCE-42FE-B40F-7CABBF597388Q36223439-73BBCF11-B89F-4E2C-A050-C122A6EFEB44Q37138794-D8194054-2A86-4137-BBA4-D0F6E7F78B73Q37149701-C381582E-EB85-4F08-8206-0BCB179A0CB0Q37216879-FECB646F-4C12-423C-9A5A-D7DA19A6C7F7Q37278241-E7866EF3-0DA9-4E4B-8C59-B0A515385EACQ37279114-CDDEE762-FFB1-4A78-9D65-9F49162AB340Q37282575-63126E65-E7D4-4C16-A8BA-3640B6A7B244Q37334120-D7B3F488-F5C8-4FEB-9AFA-0C05A1997DC5Q37380067-8F58CAF7-DB95-4F95-A4BC-93B664891C55Q37387494-12E63E53-3E5F-4F6A-A718-CC86CD63B9BDQ37399490-698D098E-FAC4-41D5-9042-77B745589599Q37432074-D0A5E952-B01A-4794-B1A2-BA3F3E0A878CQ37432086-ADC27302-D212-4B63-822D-15AABBF34CD3Q37462525-D294EDF6-235E-4023-8451-C7F92070A594Q37581346-5D361BC6-76A2-4A0F-BEDB-0297223DCC8FQ37620332-ECE1FA3D-3D89-4BE8-A1D2-8F669253AE38Q37624126-7D7B3CC4-BFF6-4222-8C70-D51AD8B77344Q37636111-AA7450D1-2696-4120-85B7-F2856D89719EQ37764961-43B7BE22-D451-441F-8C2D-7BD9B7E66470Q37768591-CBF79ED6-E7DA-41B6-BFAE-FDEC9836E369
P2860
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@ast
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@en
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@nl
type
label
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@ast
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@en
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@nl
prefLabel
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@ast
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@en
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@nl
P2093
P3181
P1476
Treatment of hepatitis B e ant ...... r adefovir: a randomized trial
@en
P2093
E Jenny Heathcote
George Harb
Gerald Y Minuk
Henry L Y Chan
Lennox Jeffers
Natalie Bzowej
Nathaniel A Brown
Patrick Marcellin
Ralf Kaiser
P304
P3181
P356
10.7326/0003-4819-147-11-200712040-00183
P407
P577
2007-12-04T00:00:00Z